^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
National Cancer Institute
Drug class:
TYRP1 inhibitor, IFNβ stimulant
Related drugs:
Phase 1
Mayo Clinic
Active, not recruiting
Last update posted :
01/09/2024
Initiation :
06/12/2019
Primary completion :
01/20/2027
Completion :
01/20/2027
BRAF
|
BRAF mutation
|
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 • Voyager-V1
Share
